Management of Adenovirus in Children after Allogeneic Hematopoietic Stem Cell Transplantation
Adenovirus (ADV) can cause significant morbidity and mortality in children following haematopoietic stem cell transplantation (HSCT), with an incidence of up to 27% and notable associated morbidity and mortality. T-cell depleted grafts and severe lymphopenia are major risk factors for the developmen...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2013-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2013/176418 |
id |
doaj-d3d0a062e35d4a4d88fc6462c2ec05da |
---|---|
record_format |
Article |
spelling |
doaj-d3d0a062e35d4a4d88fc6462c2ec05da2021-07-02T07:15:14ZengHindawi LimitedAdvances in Hematology1687-91041687-91122013-01-01201310.1155/2013/176418176418Management of Adenovirus in Children after Allogeneic Hematopoietic Stem Cell TransplantationWinnie WY Ip0Waseem Qasim1Molecular Immunology Unit, UCL Institute of Child Health, 30 Guildford Street, London WC1N 1EH, UKMolecular Immunology Unit, UCL Institute of Child Health, 30 Guildford Street, London WC1N 1EH, UKAdenovirus (ADV) can cause significant morbidity and mortality in children following haematopoietic stem cell transplantation (HSCT), with an incidence of up to 27% and notable associated morbidity and mortality. T-cell depleted grafts and severe lymphopenia are major risk factors for the development of adenovirus disease after HSCT. Current antiviral treatments are at best virostatic and may have significant side effects. Adoptive transfer of donor-derived virus-specific T cells has been shown to be an effective strategy for the prevention and treatment of ADV infection after HSCT. Here we review progress in the field and present a pathway for the management of adenovirus in the posttransplant setting.http://dx.doi.org/10.1155/2013/176418 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Winnie WY Ip Waseem Qasim |
spellingShingle |
Winnie WY Ip Waseem Qasim Management of Adenovirus in Children after Allogeneic Hematopoietic Stem Cell Transplantation Advances in Hematology |
author_facet |
Winnie WY Ip Waseem Qasim |
author_sort |
Winnie WY Ip |
title |
Management of Adenovirus in Children after Allogeneic Hematopoietic Stem Cell Transplantation |
title_short |
Management of Adenovirus in Children after Allogeneic Hematopoietic Stem Cell Transplantation |
title_full |
Management of Adenovirus in Children after Allogeneic Hematopoietic Stem Cell Transplantation |
title_fullStr |
Management of Adenovirus in Children after Allogeneic Hematopoietic Stem Cell Transplantation |
title_full_unstemmed |
Management of Adenovirus in Children after Allogeneic Hematopoietic Stem Cell Transplantation |
title_sort |
management of adenovirus in children after allogeneic hematopoietic stem cell transplantation |
publisher |
Hindawi Limited |
series |
Advances in Hematology |
issn |
1687-9104 1687-9112 |
publishDate |
2013-01-01 |
description |
Adenovirus (ADV) can cause significant morbidity and mortality in children following haematopoietic stem cell transplantation (HSCT), with an incidence of up to 27% and notable associated morbidity and mortality. T-cell depleted grafts and severe lymphopenia are major risk factors for the development of adenovirus disease after HSCT. Current antiviral treatments are at best virostatic and may have significant side effects. Adoptive transfer of donor-derived virus-specific T cells has been shown to be an effective strategy for the prevention and treatment of ADV infection after HSCT. Here we review progress in the field and present a pathway for the management of adenovirus in the posttransplant setting. |
url |
http://dx.doi.org/10.1155/2013/176418 |
work_keys_str_mv |
AT winniewyip managementofadenovirusinchildrenafterallogeneichematopoieticstemcelltransplantation AT waseemqasim managementofadenovirusinchildrenafterallogeneichematopoieticstemcelltransplantation |
_version_ |
1721336301653852160 |